PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology

BTIG analyst Mark Massaro maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price t

Explore how portfolio size and sector exposure differ between these two small-cap ETFs, each offerin

Guggenheim analyst Subbu Nambi maintains Guardant Health (NASDAQ:GH) with a Buy and raises the pr

Bernstein analyst Eve Burstein reinstates Guardant Health (NASDAQ:GH) with a Outperform and annou

Barclays analyst Luke Sergott maintains Guardant Health (NASDAQ:GH) with a Overweight and raises

RBC Capital analyst Dan Leonard initiates coverage on Guardant Health (NASDAQ:GH) with a Outperfo

Blood-based liquid biopsy test enables identification of patients eligible for treatment with HERNEX

Mizuho analyst Anthony Petrone maintains Guardant Health (NASDAQ:GH) with a Outperform and raises

Goldman Sachs analyst Evie Koslosky initiates coverage on Guardant Health (NASDAQ:GH) with a Buy

Wall Street analysts change ratings for top stocks: CRWD price target raised, FULC target lowered, H

Top Wall Street analysts upgraded GH to Outperform and raised price target to $160. Other analysts a

Wolfe Research analyst Mike Polark assumes Guardant Health (NASDAQ:GH) with a Outperform rating a

Evercore ISI Group analyst Vijay Kumar upgrades Guardant Health (NASDAQ:GH) from In-Line to Outpe

New performance data demonstrates validity of Guardant360 Liquid CDx as a comprehensive pan-cancer c

BTIG analyst Mark Massaro maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price t

Updated ACS guideline offers Shield as a new choice for over 50 million eligible Americans who are n

BTIG analyst Mark Massaro maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price t

Quantum computing, AI and semiconductor-linked stocks dominated last week's large-cap gainers as

Guardant Health secured FDA approval for Guardant360 Liquid CDx, expanding blood-based cancer profil

Guardant Health's new FDA-approved liquid biopsy integrates genomic and epigenomic insights to p

JP Morgan analyst Casey Woodring maintains Guardant Health (NASDAQ:GH) with a Overweight and rais

Barclays analyst Luke Sergott maintains Guardant Health (NASDAQ:GH) with a Overweight and raises

Evercore ISI Group analyst Daniel Markowitz maintains Guardant Health (NASDAQ:GH) with a In-Line

2026 GuidanceGuardant Health now expects full year 2026 revenue to be in the range of $1.30 to $1.32

Guardant Health (NASDAQ:GH) reported quarterly losses of $(0.45) per share which beat the analyst co

Pfizer and Arvinas secure FDA approval for VEPPANU (vepdegestrant), a first-of-its-kind treatment fo

VEPPANU, jointly developed by Arvinas, Inc. and Pfizer Inc., is approved for the treatment of adults

The collaboration reflects the growing importance of precision diagnostics in oncology drug developm

FDA highlights concerns over camizestrant data, questioning PFS relevance, OS maturity, and benefit-

Macro concerns, AI competition, and analyst downgrades drove broad weekly losses across software and

Evercore ISI Group analyst Daniel Markowitz maintains Guardant Health (NASDAQ:GH) with a In-Line

This milestone underscores the power of Guardant Health's InfinityAI platform and real-world dat

The survey showed an overwhelming majority of Americans of screening-eligible age (92%) believe that

Piper Sandler analyst David Westenberg maintains Guardant Health (NASDAQ:GH) with a Overweight an

Leerink Partners analyst Puneet Souda maintains Guardant Health (NASDAQ:GH) with a Outperform and

Citigroup analyst Patrick Donnelly maintains Guardant Health (NASDAQ:GH) with a Buy and raises th

Canaccord Genuity analyst Kyle Mikson maintains Guardant Health (NASDAQ:GH) with a Buy and raises

JP Morgan analyst Casey Woodring maintains Guardant Health (NASDAQ:GH) with a Overweight and rais

TD Cowen analyst Dan Brennan maintains Guardant Health (NASDAQ:GH) with a Buy and raises the pric

Wells Fargo analyst Brandon Couillard maintains Guardant Health (NASDAQ:GH) with a Overweight and

Stifel analyst Daniel Arias maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price

Evercore ISI Group analyst Daniel Markowitz maintains Guardant Health (NASDAQ:GH) with a In-Line

BTIG analyst Mark Massaro maintains Guardant Health (NASDAQ:GH) with a Buy and lowers the price t

Guardant Health (NASDAQ:GH) reported quarterly losses of $(0.50) per share which beat the analyst co

Baird analyst Catherine Schulte initiates coverage on Guardant Health (NASDAQ:GH) with a Outperfo

Data published in Journal of Clinical Oncology supports routine use of circulating tumor DNA (ctDNA)